Compare Eni SpA (E) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs Spyre Therapeutics Inc. Common Stock — how do they compare? Eni SpA trades at $57.39 (market cap $82.55B), while Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B). The key difference: Eni SpA is far larger — about 11.2× Spyre Therapeutics Inc. Common Stock's market cap, and Eni SpA pays a 4.23% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eni SpA for 53 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| E | SYRE | |
|---|---|---|
Market Cap | $82.55B | $7.35B |
Volume | 398,047 | 1,624,631 |
Sector | Energy | Health |
52-Week High | $57.71 | $108.92 |
52-Week Low | $34.20 | $22.18 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $107.08B | $6.35B |
Dividend Yield | 4.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $57.45, up 1.2% today, with a bullish technical signal from moving averages. Revenue has declined from $132.5B in 2022 to $82.15B in 2025, though net income margin improved to 5.97% in 2026. Recent news highlights expansion in humanoid robotics, LNG projects, and fuel discounts, while earnings missed expectations in Q1 and Q2 2026.
The stock presents a mixed outlook: attractive valuation with a P/E of 13.47 and strong cash flow support dividend stability, but revenue declines and earnings misses pose risks. Analyst consensus is cautious with 62% hold ratings. Key opportunities include strategic expansions, while risks involve volatile energy prices and execution challenges.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
